Sickle hemoglobinopathies
Related Experiment Video
Updated: Nov 7, 2026

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
1Colorado Sickle Cell Treatment and Research Center, University of Colorado Health Sciences Center, Denver 80262.
Insights
Neonatal screening and comprehensive care significantly reduce sickle hemoglobinopathy mortality. However, new research offers hope for better management of complications and potential curative therapies.
Area of Science:
- Hematology
- Pediatric Medicine
- Genetics
Background:
- Neonatal screening and comprehensive care, including penicillin prophylaxis and immunizations, have greatly decreased infant mortality from sickle hemoglobinopathies.
- Despite advances in understanding pathophysiology, current treatments inadequately prevent acute noninfectious complications (e.g., pain crises, strokes) and chronic organ damage.
Purpose of the Study:
- To review recent advancements in understanding sickle hemoglobinopathies.
- To highlight improvements in managing acute complications and the emergence of potentially curative therapies.
Main Methods:
- Review of recent publications on sickle hemoglobinopathies.
- Analysis of current therapeutic approaches and ongoing clinical trials.
Main Results:
- Increased knowledge of factors contributing to clinical heterogeneity in sickle hemoglobinopathies.
- Modest improvements in identifying and treating acute complications.
- Emerging hope for curative treatments, with ongoing trials for hydroxyurea and bone marrow transplantation.
Conclusions:
- While neonatal screening and supportive care have improved survival, significant challenges remain in managing disease complications.
- Recent research offers promising avenues for more effective treatments and potential cures for sickle hemoglobinopathies.
Abstract:
Neonatal screening for hemoglobinopathies, coupled with comprehensive medical care that includes parental education, prophylactic penicillin, and immunizations, has markedly reduced mortality from sickle hemoglobinopathies during infancy and early childhood. However, despite an increased knowledge of pathophysiology, current therapy does little to prevent acute, noninfectious complications such as anemic crises, pain events, or strokes; nor does it reliably prevent or delay the development of chronic organ damage. Recent publications have increased our understanding of factors that contribute to the clinical heterogeneity of sickle hemoglobinopathies, improved modestly our ability to identify and treat acute complications, and provided real hope for the development of potentially curative therapies. Prospective therapeutic trials of hydroxyurea and of bone marrow transplantation have recently begun.
Related Concept Videos
Multiple Allele Traits
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Hemoglobin
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
